{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T20:26:11Z","timestamp":1789935971502,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.clinthera.2005.05.004","type":"journal-article","created":{"date-parts":[[2005,6,23]],"date-time":"2005-06-23T07:21:43Z","timestamp":1119511303000},"page":"599-608","source":"Crossref","is-referenced-by-count":52,"title":["Cefepime and continuous renal replacement therapy (CRRT): In vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients"],"prefix":"10.1016","volume":"27","author":[{"given":"Arantxazu","family":"Isla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia Rodr\u00edguez","family":"Gasc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Maynar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alazne","family":"Arzuaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dar\u00edo","family":"Toral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Pedraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2005.05.004_bib1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003495-199447030-00007","article-title":"Cefepime. A review of its antibacterial activity, pharmacokinetic profile and therapeutic use","volume":"47","author":"Barradell","year":"1994","journal-title":"Drugs"},{"issue":"Suppl A","key":"10.1016\/j.clinthera.2005.05.004_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/29.suppl_A.1","article-title":"Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins","volume":"29","author":"Hancock","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.05.004_bib3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1128\/AAC.43.1.129","article-title":"Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model","volume":"43","author":"Cappelletty","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.05.004_bib4","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1128\/AAC.45.11.3148-3155.2001","article-title":"Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients","volume":"45","author":"Malone","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.05.004_bib5","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1128\/AAC.43.10.2559","article-title":"Low plasma cefepime levels in critically ill septic patients: Pharmacokinetic modeling indicates improved troughs with revised dosing","volume":"43","author":"Lipman","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.05.004_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jac\/32.suppl_B.103","article-title":"Pharmacokinetics of cefepime: A review","volume":"32","author":"Van der Auwera","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.05.004_bib7","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1128\/AAC.41.11.2424","article-title":"Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration","volume":"41","author":"Allaouchiche","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.05.004_bib8","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1373\/49.6.1011","article-title":"Reevaluation of formulas for predicting creatinine clearance in adults and children, using compensated creatinine methods","volume":"49","author":"Wuyts","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinthera.2005.05.004_bib9","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1023\/A:1007669411738","article-title":"Bioanalytical method validation\u2014a revisit with a decade of progress","volume":"17","author":"Shah","year":"2000","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2005.05.004_bib10","series-title":"Guidance for Industry: Bioanalytical Methods Validation for Human Studies","author":"US Food and Drug Administration","year":"1998"},{"key":"10.1016\/j.clinthera.2005.05.004_bib11","first-page":"307","article-title":"Drug removal during continuous arteriovenous hemofiltration: Theory and clinical observations","volume":"8","author":"Golper","year":"1985","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.clinthera.2005.05.004_bib12","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/jps.2600720843","article-title":"Computation of model-independent pharmacokinetic parameters during multiple dosing","volume":"72","author":"Bauer","year":"1983","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2005.05.004_bib13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2165\/00003088-198409010-00003","article-title":"Drug therapy in patients undergoing hemodialysis: Clinical pharmacokinetic considerations","volume":"9","author":"Lee","year":"1984","journal-title":"Clin Pharm"},{"key":"10.1016\/j.clinthera.2005.05.004_bib14","first-page":"748","article-title":"Drug administration in critically ill patients with acute renal failure","volume":"3","author":"Kroh","year":"1995","journal-title":"New Horiz"},{"key":"10.1016\/j.clinthera.2005.05.004_bib15","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1128\/AAC.42.9.2421","article-title":"Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration","volume":"42","author":"Krueger","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.05.004_bib16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000420197","article-title":"Drug removal during continuous hemofiltration or hemodialysis","volume":"93","author":"Golper","year":"1991","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.clinthera.2005.05.004_bib17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1128\/AAC.36.2.453","article-title":"Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid","volume":"36","author":"Kalman","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.05.004_bib18","doi-asserted-by":"crossref","first-page":"M691","DOI":"10.1097\/00002480-199207000-00127","article-title":"Dialysate and blood flow dependence of diffusive solute clearance during CVVHD","volume":"38","author":"Relton","year":"1992","journal-title":"ASAIO J"},{"key":"10.1016\/j.clinthera.2005.05.004_bib19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/j.1552-4604.1986.tb02973.x","article-title":"Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients","volume":"26","author":"Zarowitz","year":"1986","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2005.05.004_bib20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000168858","article-title":"Elimination of flucytosine by continuous hemofiltration","volume":"15","author":"Lau","year":"1995","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.clinthera.2005.05.004_bib21","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/00003246-199205000-00007","article-title":"Gentamicin clearance during continuous arteriovenous hemodiafiltration","volume":"20","author":"Emest","year":"1992","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clinthera.2005.05.004_bib22","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1053\/ajkd.1998.v31.pm9631848","article-title":"Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis","volume":"31","author":"Joy","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2005.05.004_bib23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1592\/phco.20.7.635.35170","article-title":"Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis","volume":"20","author":"Matzke","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2005.05.004_bib24","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1128\/AAC.44.6.1639-1644.2000","article-title":"Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis","volume":"44","author":"Matzke","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2005.05.004_bib25","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/jac\/32.suppl_B.117","article-title":"Pharmacokinetics of cefepime in patients with the sepsis syndrome","volume":"32","author":"Kieft","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2005.05.004_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/bjs.4790","article-title":"Randomized clinical trial of the effect of intravenous fluid administration on hormonal and renal dysfunction in patients with obstructive jaundice undergoing endoscopic drainage","volume":"92","author":"Padillo","year":"2005","journal-title":"Br J Surg"},{"key":"10.1016\/j.clinthera.2005.05.004_bib27","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0002-9610(00)00388-3","article-title":"Intermittent and continuous ceftazidime infusion for critically ill trauma patients","volume":"179","author":"Hanes","year":"2000","journal-title":"Am J Surg"},{"key":"10.1016\/j.clinthera.2005.05.004_bib28","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/0091270004269796","article-title":"Influence of renal function on the pharmacokinetics of piperacillin\/tazobactam in intensive care unit patients during continuous venovenous hemofiltration","volume":"45","author":"Arzuaga","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2005.05.004_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00005373-199201000-00005","article-title":"The pharmacokinetics of prophylactic antibiotics in trauma","volume":"32","author":"Reed","year":"1992","journal-title":"J Trauma"},{"key":"10.1016\/j.clinthera.2005.05.004_bib30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00003246-198902000-00010","article-title":"Aminoglycoside pharmacokinetics: Dosage requirements and nephrotoxicity in trauma patients","volume":"17","author":"Townsend","year":"1989","journal-title":"Crit Care Med"},{"key":"10.1016\/j.clinthera.2005.05.004_bib31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/BF01712162","article-title":"Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient","volume":"22","author":"Botha","year":"1996","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.clinthera.2005.05.004_bib32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2710.1996.tb00041.x","article-title":"Pharmacokinetics of amikacin in intensive care patients","volume":"21","author":"Fernandez de Gatta","year":"1996","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2005.05.004_bib33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-199528020-00005","article-title":"The importance of pharmacokinetic\/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents","volume":"28","author":"Hyatt","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2005.05.004_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","article-title":"Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins","volume":"22","author":"Craig","year":"1995","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2005.05.004_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2005.05.004_bib36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0210-5691(02)79735-0","article-title":"Estudio nacional de vigilancia de infecci\u00f3n nosocomial en unidades de cuidados intensivos. Informe del a\u00f1o 2000","volume":"26","author":"\u00c1lvarez-Lerma","year":"2002","journal-title":"Medicina Intensiva"},{"key":"10.1016\/j.clinthera.2005.05.004_bib37","series-title":"Performance Standards for Antimicrobial Susceptibility Testing; Fourteenth Informational Supplement","author":"National Committee for Clinical Laboratory Standards","year":"2004"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805000809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805000809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T18:38:32Z","timestamp":1551292712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291805000809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0149291805000809"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2005.05.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}